AURX (Nuo Therapeutics) Other Financing: $0.00 Mil (TTM As of Mar. 2026)


AURX Nuo Therapeutics Inc AURX
33 GF Score
Price $0.92
GF Value $4.27
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Nuo Therapeutics Other Financing?

Nuo Therapeutics AURX 33 Other Financing is $0.00 Mil as of Mar. 2026. GuruFocus rates AURX with a GF Score™ of 33/100 and a GF Value™ of $4.27 (Possible Value Trap). The stock has 4 warning signs investors should review.

Nuo Therapeutics's Other Financing for the three months ended in Mar. 2026 was $0.00 Mil.

Nuo Therapeutics's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil.

Nuo Therapeutics Other Financing Historical Data

* Premium members only.

The historical data trend for Nuo Therapeutics's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nuo Therapeutics Other Financing Chart

Nuo Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.24 0.11

Nuo Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
AURX
33GF Score
Nuo Therapeutics Inc AURX
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nuo Therapeutics Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $0.00 Mil mean?
Nuo Therapeutics (AURX) has a Other Financing of $0.00 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Nuo Therapeutics and its competitors.
Is Nuo Therapeutics' Other Financing too high?
Nuo Therapeutics' current Other Financing is $0.00 Mil. Overall, Nuo Therapeutics has a GF Score™ of 33/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nuo Therapeutics' Other Financing compare to PDSB and LTRN?
Nuo Therapeutics' Other Financing of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Nuo Therapeutics and its competitors. Nuo Therapeutics's current Other Financing is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nuo Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Nuo Therapeutics (AURX) is currently considered Possible Value Trap. The stock's GF Value™ is $4.27, compared to a current price of $0.92 — trading 78.5% below its estimated fair value. The current Other Financing is $0.00 Mil. Nuo Therapeutics' overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Nuo Therapeutics (AURX), the current Other Financing is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nuo Therapeutics (AURX) Overvalued in 2026?

Based on GuruFocus' analysis, Nuo Therapeutics stock appears to be undervalued. The current stock price of $0.92 is trading 78.5% below its estimated GF Value™ of $4.27. GuruFocus considers Nuo Therapeutics to be Possible Value Trap.

Key valuation signals for AURX:

  • Other Financing: $0.00 Mil
  • GF Value™: $4.27 vs. price of $0.92 (78.5% below fair value)
  • GF Score™: 33/100 with 4 warning signs

No single metric tells the full story. See the AURX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nuo Therapeutics Business Description

Address 8285 El Rio Street, Suite 190, Houston, TX, USA, 77054
Nuo Therapeutics Inc is a commercial-stage medical device company engaged in developing and marketing products for chronic wound care. The company operates as a single segment focused on regenerative therapies that utilize autologous (patient-derived) biological materials to promote natural healing. Its primary commercial product is the Aurix System, a point-of-care technology that produces platelet-rich plasma (PRP) therapy from a patient's own blood for use in the treatment of chronic wounds.
33GF Score

Get the complete analysis for AURX

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.92
Price
$4.27
GF Value